# Coherus Oncology, Inc. Common Stock (CHRS)

> Coherus Oncology, Inc. Common Stock (CHRS) trades at $0.3698 (-4.47%) as of 7:30:06 PM EST on Nov 20, 2026, -64.78% over the past month. Market cap is $57.15M, with 8.2 days to cover in short interest.

Canonical: https://massive.com/quote/chrs
Data as of: 2026-11-21T00:30:06.407Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.3698** -0.02 (-4.47%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$0.3799** +0.01 (+2.73%)
As of 7:30:06 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Coherus Oncology, Inc. Common Stock (CHRS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -4.47% |
| 1W | -29.63% |
| 1M | -64.78% |
| YTD | -73.96% |
| 1Y | -71.11% |
| 52-wk range | $0.36 – $2.62 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for CHRS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.36 – $0.41 |
| Open | $0.39 |
| Prev close | $0.39 |
| Volume | 2.52M |
| Market cap | $57.15M |
| Shares out | 154.5M |

## Valuation and profitability ratios

Valuation and profitability ratios for Coherus Oncology, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 1.07 |
| P/B | 2.26 |
| P/FCF | — |
| ROE | -538.4% |
| ROA | -79.5% |
| Debt/Equity | 2.08 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Coherus Oncology, Inc. Common Stock (CHRS) insider trading](https://massive.com/quote/chrs/insider-trading.md): open-market Form 4 buys and sells by Coherus Oncology, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Coherus Oncology, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 9, 2026, Coherus Oncology, Inc. (the "Company") issued a press release regarding its financial results for the quarter ended September 30, 2026.”
- Oct 29, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “In second-line ESCC, 17 patients were safety evaluable and 8 were efficacy evaluable; in the 700 mg tagmokitug dose arm, the clinical benefit rate was 33.3%, cORR was 16.7%, and median progression-free survival was 5.5 months.”
- Aug 28, 2026 · Underwriting agreement
  “Under the Sales Agreement, the Agent may sell Shares by any method permitted by law deemed to be an "at the market offering" under Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). The Company will pay the Agent a commission up to 3.0% of the gross proceeds from each sale of Shares and provide the Agent with customary indemnification and contribution rights.”
- Aug 17, 2026 · Debt retirement
  “A portion of the Tranche A Term Loan proceeds was used to repay all obligations under the Company's existing senior secured term loan facility (the "Prior Loan Agreement"), which accrued interest at a rate equal to 8.0%, plus a three-month SOFR rate per annum, and was scheduled to mature in May 2029.”
- Aug 17, 2026 · Credit facility
  “The Company is party to the Loan and Security Agreement, dated as of August 12, 2026, with Innovatus Life Sciences Lending Fund I, L.P., as collateral agent, and the lenders thereunder (the 'Loan Agreement'), which contains certain restrictions on the disposition of the Legacy BioSim Assets and payments under the CVR.”

## CHRS short interest

How heavily CHRS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.2 |
| Short interest | 12.71M |
| Avg volume | 1.55M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## CHRS news

The latest news and headlines about Coherus Oncology, Inc. Common Stock (CHRS).

- [Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now](https://www.zacks.com/stock/news/3031797/here-s-why-coherus-oncology-chrs-is-a-great-buy-the-bottom-stock-now?cid=CS-ZC-FT-fundamental_analysis|hammer_chart_pattern_%28ta%29-3031797) · Zacks Investment Research · Nov 18, 2026 · positive sentiment
- [Coherus Oncology: 3 Key Takeaways for Long-Term Investors](https://www.fool.com/earnings/takeaways/2026/11/10/coherus-oncology-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001) · The Motley Fool · Nov 10, 2026 · negative sentiment
- [Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3026831/coherus-oncology-chrs-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3026831) · Zacks Investment Research · Nov 9, 2026 · negative sentiment
- [Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026](https://www.globenewswire.com/news-release/2026/07/22/3331650/33333/en/Coherus-Oncology-to-Report-Second-Quarter-2026-Financial-Results-on-August-5-2026.html) · GlobeNewswire Inc. · Jul 22, 2026 · neutral sentiment
- [Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)](https://www.globenewswire.com/news-release/2026/06/23/3316369/33333/en/Coherus-and-Zumutor-Biologics-Announce-Clinical-Collaboration-to-Evaluate-ZM008-in-Combination-with-LOQTORZI-toripalimab-tpzi.html) · GlobeNewswire Inc. · Jun 23, 2026 · positive sentiment

## About Coherus Oncology, Inc. Common Stock

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 145 |
| Listed | Nov 6, 2014 |

[Company website](https://www.coherus.com)

## FAQ

### What is the Coherus Oncology, Inc. Common Stock (CHRS) stock price today?

Coherus Oncology, Inc. Common Stock (CHRS) is trading at $0.3698 (-4.47% on the day) as of 7:30:06 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Coherus Oncology, Inc. Common Stock?

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers.

### What is the short interest in CHRS?

As of Oct 30, 2026, CHRS has 12.71M shares short and 8.2 days to cover.

### What exchange is CHRS listed on?

Coherus Oncology, Inc. Common Stock (CHRS) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time CHRS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=CHRS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Coherus Oncology, Inc. Common Stock (CHRS) insider trading](https://massive.com/quote/chrs/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
